The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.
Event:
ESC Congress 2022
Topic:
Antidiabetic Pharmacotherapy
Session:
Anti-diabetic pharmacotherapy in clinical practice
